MTL 005

Drug Profile

MTL 005

Alternative Names: MTL-005

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morvus Technology
  • Developer MorEx Development Partners
  • Class Metalloporphyrins; Radiation-sensitising agents; Radiosensitisers
  • Mechanism of Action Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Breast cancer; Head and neck cancer

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for preclinical development in Breast-cancer in United Kingdom (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer in United Kingdom (Parenteral, Injection)
  • 26 Mar 2015 MTL 005 is available for licensing as of 26 Mar 2015. http://www.morexdevelopments.com/partnering.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top